瑞普生物(300119) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥442,780,482.14, representing a 13.30% increase compared to ¥390,806,576.59 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥80,823,461.46, up 11.93% from ¥72,205,916.82 year-on-year[4] - Total operating revenue for Q1 2023 reached ¥442,780,482.14, an increase of 13.3% compared to ¥390,806,576.59 in the same period last year[24] - The net profit for Q1 2023 was CNY 87,502,825.62, an increase of 9.4% compared to CNY 79,588,705.19 in Q1 2022[26] - The operating profit for the quarter was CNY 98,534,255.21, up from CNY 84,660,247.50 in the same period last year, reflecting a growth of 16.5%[26] - The total comprehensive income for the quarter was CNY 87,502,825.62, compared to CNY 79,588,705.19 in Q1 2022, indicating a growth of 9.4%[27] Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥29,212,171.85, a 153.56% increase from a negative cash flow of -¥54,538,255.13 in the previous year[4] - The company's cash and cash equivalents decreased by 90.36% to -¥54,701,596.71, influenced by comprehensive cash flow impacts from operating, investing, and financing activities[9] - The company's cash and cash equivalents at the end of the period were CNY 322,003,336.23, down from CNY 713,057,275.43 at the end of Q1 2022[30] - The company's cash and cash equivalents decreased to ¥326,287,013.13 from ¥384,421,438.29 at the beginning of the year, a decline of 15.1%[21] - The total assets at the end of Q1 2023 were ¥6,029,891,650.30, a decrease of 1.25% from ¥6,106,273,672.25 at the end of the previous year[4] - The total liabilities decreased to ¥1,444,277,569.81 from ¥1,605,173,462.21, a reduction of 10%[22] Research and Development - Research and development expenses rose to ¥32,060,179.48, marking a 48.77% increase compared to ¥21,549,970.45 in the prior year, reflecting enhanced R&D efforts[9] - Research and development expenses increased to ¥32,060,179.48, representing a 48.8% rise from ¥21,549,970.45 in the previous year[24] - The company has established a mechanism for shared research and development resources with Shengwei Biological[17] Strategic Initiatives - The company invested CNY 63 million to acquire a 15% stake in Fujian Shengwei Biological Technology Co., Ltd., aiming to establish a comprehensive strategic partnership[17] - A strategic cooperation agreement and an asset leasing framework agreement were signed with Fujian Shengnong Development Co., Ltd. and Shengwei Biological, enhancing collaboration in healthy farming practices[18] - The company aims to expand its sales scale and brand influence through strategic partnerships and resource sharing[18] - The company is focused on innovation in product development and marketing strategies to enhance customer service[17] - The company is committed to strengthening its market position in poultry disease prevention[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,706[10] - The total number of restricted shares at the end of the period was 133,708,900 shares, with 11,242,492 shares released during the reporting period[14] - The top 10 unrestricted shareholders held a total of 144,951,392 shares, with the largest shareholder holding 41,868,620 shares[13] - The company reported no changes in the number of preferred shareholders during the period[12] Inventory and Expenses - The company reported a significant increase in inventory, which rose to ¥402,264,003.91 from ¥367,055,974.97, an increase of 9.5%[21] - Total operating costs for Q1 2023 were ¥361,812,573.71, up 15.4% from ¥313,567,270.68 in Q1 2022[24] - The company experienced a 140.15% increase in financial expenses, totaling ¥5,133,553.03, primarily due to reduced bank deposits and interest income[9]